CYFRA 21-1: A potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder

References

• Andreadis C, Touloupidis S, Galaktidou G, Kortsaris AH, Boutis A, Mouratidou D. (2005). Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J Urol 174:1771–5; discussion 1775.
   PubMedGoogle Scholar
• Badjatia N, Satyam A, Singh P, Seth A, Sharma A. (2010). Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol 28:360–367.
   PubMed Web of Science ®Google Scholar
• Bjorklund B, Bjorklund V. (1957). Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: Presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy Appl Immunol 10:153–184.
   PubMedGoogle Scholar
• Bodenmüller H. (1995). The biochemistry of CYFRA 21-1 and other cytokeratin-tests. Scand J Clin Lab Invest Suppl 221:60–66.
   PubMedGoogle Scholar
• Chao D, Freedland SJ, Pantuck AJ, Zisman A, Belldegrun AS. (2001). Bladder cancer 2000: Molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol 3:85–93.
   PubMedGoogle Scholar
• Cooper D, Schermer A, Sun TT. (1985). Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: Strategies, applications, and limitations. Lab Invest 52:243–256.
   PubMed Web of Science ®Google Scholar
• Dittadi R, Barioli P, Gion M, Mione R, Barichello M, Capitanio G, Cocco G, Cazzolato G, De Biasi F, Praturlon S, Antinozzi R, Gianneo E. (1996). Standardization of assay for cytokeratin-related tumor marker CYFRA 21.1 in urine samples. Clin Chem 42:1634–1638.
   PubMedGoogle Scholar
• Droller MJ. (1998). Bladder cancer: State-of-the-art care. CA Cancer J Clin 48:269–284.
   PubMed Web of Science ®Google Scholar
• Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, Kauppinen S, Ulhøi BP, Kjems J, Borre M, Orntoft TF. (2009). Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69:4851–4860.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. (2001). The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer 11:277–282.
   PubMed Web of Science ®Google Scholar
• Konety BR, Getzenberg RH. (2001). Urine based markers of urological malignancy. J Urol 165:600–611.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Griffith JG. (1992). Intravesical therapy: Does it affect the natural history of superficial bladder cancer? Semin Urol 10:39–44.
   PubMedGoogle Scholar
• Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, Duncan RC, Soloway MS, Block NL. (2000). Urinary hyaluronic acid and hyaluronidase: Markers for bladder cancer detection and evaluation of grade. j Urol 163:348–356.
   PubMed Web of Science ®Google Scholar
• MacVicar AD. (2000). Bladder cancer staging. BJU Int 86 Suppl 1:111–122.
   PubMedGoogle Scholar
• Messing EM, Catalona W. (1998). Urothelial Tumors Of The Urinary Tract, In: Walsh PC, Retik AB, Vaughan ED, et al., eds. Campbell’s Urology, 7th edn, vol 3. Philadelphia, WB Saunders Company, pp. 2329–2421.
   Google Scholar
• Metts MC, Metts JC, Milito SJ, Thomas CR Jr. (2000). Bladder cancer: A review of diagnosis and management. J Natl Med Assoc 92:285–294.
   Google Scholar
• Mian C, Lodde M, Haitel A, Vigl EE, Marberger M, Pycha A. (2000). Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 55:223–226.
   PubMed Web of Science ®Google Scholar
• Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. (1999). Immunocyt: A new tool for detecting transitional cell cancer of the urinary tract. J Urol 161:1486–1489.
   PubMed Web of Science ®Google Scholar
• Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. (1982). The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11–24.
   PubMed Web of Science ®Google Scholar
• Morsi MI, Youssef AI, Hassouna ME, El-Sedafi AS, Ghazal AA, Zaher ER. (2006). Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients. J Egypt Natl Canc Inst 18:82–92.
   PubMedGoogle Scholar
• Nakata B, Chung YS, Kato Y, Ogawa M, Ogawa Y, Inui A, Maeda K, Sawada T, Sowa M. (1996). Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 73:1529–1532.
   PubMedGoogle Scholar
• Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, Hirakawa K. (2000). Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89:1285–1290.
   PubMed Web of Science ®Google Scholar
• Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J. (1995). Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J 8:291–294.
   PubMedGoogle Scholar
• Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D. (2002). Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94:2914–2922.
   PubMed Web of Science ®Google Scholar
• Pariente JL, Bordenave L, Jacob F, Gobinet A, Leger F, Ferriere JM, Le Guillou M. (2000). Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J Urol 163:1116–1119.
   PubMed Web of Science ®Google Scholar
• Pariente JL, Bordenave L, Michel P, Latapie MJ, Ducassou D, Le Guillou M. (1997). Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 158:338–341.
   PubMed Web of Science ®Google Scholar
• Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O’Kane DJ. (1999). Comparison of screening methods in the detection of bladder cancer. J Urol 161:388–394.
   PubMed Web of Science ®Google Scholar
• Sánchez-Carbayo M, Herrero E, Megías J, Mira A, Soria F. (1999). Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 162:1951–1956.
   PubMed Web of Science ®Google Scholar
• Sánchez-Carbayo M, Urrutia M, González de Buitrago JM, Navajo JA. (2001). Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 92:2820–2828.
   PubMedGoogle Scholar
• Sánchez-Carbayo M, Urrutia M, Silva JM, Romaní R, García J, Alférez F, González deBuitrago JM, Navajo JA. (2000). Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer. Urology 55:526–532.
   PubMedGoogle Scholar
• Satyam A, Singh P, Badjatia N, Seth A, Sharma A. (2011). A disproportion of Th1/Th2 cytokines with predominance of Th2, in urothelial carcinoma of bladder. Urol Oncol 29:58–65.
   PubMed Web of Science ®Google Scholar
• Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, Neuhaus J, Stolzenburg JU, Conaway MR, Mischak H, Theodorescu D. (2009). Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res 15:4935–4943.
   PubMed Web of Science ®Google Scholar
• Southgate J, Harnden P, Trejdosiewicz LK. (1999). Cytokeratin expression patterns in normal and malignant urothelium: A review of the biological and diagnostic implications. Histol Histopathol 14:657–664.
   PubMed Web of Science ®Google Scholar
• Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS. (1998). Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159:394–398.
   PubMed Web of Science ®Google Scholar
• Stieber P, Dienemann H, Hasholzner U, Fabricius PG, Schambeck C, Weinzierl M, Poley S, Samtleben W, Hofmann K, Meier W. (1994). Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers 9:82–88.
   PubMedGoogle Scholar
• Theyer G, Dürer A, Theyer U, Haberl I, Ulsperger E, Baumgartner G, Hamilton G. (1999). Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy. Prostate 41:71–77.
   PubMedGoogle Scholar
• Wang R, Morris DS, Tomlins SA, Lonigro RJ, Tsodikov A, Mehra R, Giordano TJ, Kunju LP, Lee CT, Weizer AZ, Chinnaiyan AM. (2009). Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. Cancer Res 69:3810–3818.
   PubMedGoogle Scholar
• Weber K, Osborn M, Moll R, Wiklund B, Lüning B. (1984). Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: Re-evaluation of a human tumor marker. Embo J 3:2707–2714.
   PubMed Web of Science ®Google Scholar
• Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, Steiner I, Zwarthoff EC, Burger M, Denzinger S, Hofstaedter F, Kristiansen G, Hermanns T, Seifert HH, Provenzano M, Sulser T, Roth V, Buhmann JM, Moch H, Hartmann A. (2009). Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev 18:1798–1806.
   PubMed Web of Science ®Google Scholar